Libtayo (cemiplimab) vs Vegzelma (bevacizumab-adcd)
Libtayo (cemiplimab) vs Vegzelma (bevacizumab-adcd)
Libtayo (cemiplimab) is an immune checkpoint inhibitor specifically designed to target and block the PD-1 receptor on T-cells, thereby enhancing the immune system's ability to attack cancer cells; it is primarily used for the treatment of certain types of skin cancers and non-small cell lung cancer. Vegzelma (bevacizumab-adcd) is a biosimilar to the original bevacizumab (Avastin), which works by inhibiting vascular endothelial growth factor (VEGF), thus preventing the growth of blood vessels that supply tumors; it is used in various cancer types, including colorectal, lung, glioblastoma, kidney, and cervical cancers. When deciding between the two, it is crucial to consider the specific type of cancer being treated, as their mechanisms of action are different and they are approved for different indications; a healthcare provider would offer guidance based on the individual's cancer type, stage, previous treatments, and overall health status.
Difference between Libtayo and Vegzelma
| Metric | Libtayo (cemiplimab) | Vegzelma (bevacizumab-adcd) |
|---|---|---|
| Generic name | Cemiplimab | Bevacizumab-adcd |
| Indications | Cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer | Metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer |
| Mechanism of action | Programmed death receptor-1 (PD-1) blocking antibody | Vascular endothelial growth factor (VEGF) inhibitor |
| Brand names | Libtayo | Vegzelma |
| Administrative route | Injection (intravenous) | Injection (intravenous) |
| Side effects | Fatigue, rash, diarrhea, musculoskeletal pain | Hypertension, fatigue, diarrhea, decreased appetite |
| Contraindications | None known | None known |
| Drug class | Monoclonal antibody, PD-1 inhibitor | Monoclonal antibody, VEGF inhibitor |
| Manufacturer | Regeneron Pharmaceuticals, Inc. | Celltrion Healthcare Co., Ltd. |
Efficacy
Libtayo (Cemiplimab) Efficacy in Lung Cancer
Libtayo (cemiplimab) is a fully human monoclonal antibody that has been designed to target and block the PD-1 receptor on T cells. By doing so, it enhances the body's immune response against cancer cells. The efficacy of Libtayo in the treatment of lung cancer, specifically non-small cell lung cancer (NSCLC), has been evaluated in several clinical trials. In a pivotal phase 3 trial, cemiplimab demonstrated a significant improvement in overall survival in patients with advanced NSCLC with PD-L1 expression on at least 50% of tumor cells, who were previously untreated. This improvement was observed in comparison to those receiving chemotherapy.
The trial's results showed that patients treated with Libtayo had a median overall survival of 22.1 months, compared to 14.3 months for those on chemotherapy. Furthermore, the progression-free survival (PFS) was also notably longer in the Libtayo group. These findings suggest that Libtayo can be an effective first-line treatment option for patients with high PD-L1 expression in advanced NSCLC.
Vegzelma (Bevacizumab-adcd) Efficacy in Lung Cancer
Vegzelma (bevacizumab-adcd) is a biosimilar to the original bevacizumab product, which is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). By blocking VEGF, Vegzelma helps prevent the growth of blood vessels that supply tumors, thereby inhibiting tumor growth. In the context of lung cancer, specifically non-squamous non-small cell lung cancer (NSCLC), bevacizumab has been studied in combination with chemotherapy and has been shown to improve outcomes for patients.
In pivotal clinical studies, bevacizumab, when combined with carboplatin and paclitaxel, resulted in an extension of progression-free survival and overall survival compared to chemotherapy alone. Patients receiving the combination with bevacizumab experienced a median overall survival of around 12.3 months, while those on chemotherapy alone had a median overall survival of 10.3 months. These results have established the combination of bevacizumab with chemotherapy as a standard treatment option for patients with advanced non-squamous NSCLC.
Regulatory Agency Approvals
Libtayo
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
Vegzelma
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Libtayo or Vegzelma today
If Libtayo or Vegzelma are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us